



**APITOPE TO PRESENT AT BIOEQUITY EUROPE CONFERENCE ON
19 MAY 2010, 15.30 (CET)**

Bristol, UK / Hasselt, Belgium – 14 May 2010: Apitope International N.V., the autoimmune peptide therapy company, announces today that Dr. Keith Martin, CEO, will give an overview of the Company's business at 'BioEquity Europe 2010'. The presentation will be at the Swissôtel Zurich, Switzerland at 15.30 (CET) on Wednesday, 19 May 2010.

The presentation will focus on Apitope's development of therapeutic peptides for revolutionary treatment of autoimmune diseases and allergies.

For more information, please go to www.biocentury.com

For further information:

**Apitope International N.V.
Dr. Keith Martin, CEO
+44 117 903 1119**

**Capital MS&L Limited
Mary Clark, Head of Life Sciences
+44 20 7307 5330**

keith.martin@apitope.com

mary.clark@capitalmsl.com

About Apitope

Apitope is a European biotechnology company focusing on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves' disease. It has headquarters in Hasselt, Belgium and a subsidiary in Bristol, UK.

The Company is developing potential therapies to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.

Its patented, leading edge, high speed discovery platform enables it to identify and design innovative peptide-based therapies and diagnostics and it has an impressive pipeline of products in development.

Apitope has a highly experienced management team, with a proven track record in discovering and developing innovative therapeutics.

For more information, please go to www.apitope.com